You can seek FDA approval to launch a generic drug before the expiration of ABILIFY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of ACULAR LS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ACULAR LS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ACULAR LS:-

You can seek FDA approval to launch a generic drug before the expiration of AMPYRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AMPYRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AMPYRA:-

You can seek FDA approval to launch a generic drug before the expiration of DIPRIVAN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DIPRIVAN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DIPRIVAN:-

You can seek FDA approval to launch a generic drug before the expiration of FENOGLIDE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FENOGLIDE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FENOGLIDE:-

You can seek FDA approval to launch a generic drug before the expiration of MOVANTIK's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MOVANTIK's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MOVANTIK:-

You can seek FDA approval to launch a generic drug before the expiration of REMODULIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REMODULIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REMODULIN:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of REVLIMID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REVLIMID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REVLIMID:-

You can seek FDA approval to launch a generic drug before the expiration of SAXENDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAXENDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAXENDA:-

You can seek FDA approval to launch a generic drug before the expiration of VICTOZA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VICTOZA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VICTOZA:-

You can seek FDA approval to launch a generic drug before the expiration of XYREM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XYREM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XYREM:-